ClinicalTrials.gg
CompletedNCT04646993WHITEUpdated Mar 11, 2022

WHITE Study: WHIch Decision After a First Venous ThromboEmbolism?

An observational study in Venous Thromboembolism, sponsored by Arianna Anticoagulazione Foundation. Completed at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-11.

Sponsored by Arianna Anticoagulazione Foundation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Venous Thromboembolism with a site in Czechia — 2 open to participants now, 2 under way, none of them phase 3. Venous Thromboembolism · Czechia.

Started
2018
the only one that year
Observational
5 of 34
1 open now
Registered
31st of 34
by date
Lead sponsor
1 of 34
Arianna Anticoagulazione Foundation

Among the 34 studies in Venous Thromboembolism with a site in Czechia, this one is the only one that started in 2018, is one of 5 observational ones, and was the 31st registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

2 of the 34 studies in Venous Thromboembolism with a site in Czechia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Venous Thromboembolism with a site in Czechia, or all of them as a file.
02

Study summary

The WHITE study is a multicenter, multinational, investigators-initiated, observational, prospective study conducted in a consecutive series of ambulatory patients who had completed the recommended or practicable period of anticoagulation after a first-ever episode of venous thromboembolism (VTE)

The general aim of the study is to evaluate the distribution of decisions and of the reasons guiding the physician's decision on the modality to manage the secondary prevention of VTE in patients treated for a first-ever episode of VTE, after the initial 3-12 months of anticoagulant therapy.

Read the detailed description

The WHITE study is an international, non-profit, multicenter, observational, prospective and no profit study 3,200 subjects having experienced a first-ever episode of DVT of the lower limbs and/or PE, receive anticoagulation therapy for a period as recommended by international and/or local practice guidelines will be enrolled across all the countries participating to the study.

When this recommended period expires, the attending physician has to decide whether to continue with anticoagulation, switch to anti-thrombotic of another class, or stop any prophylactic pharmacological treatment.

The primary objective of the study is the evaluation of the distribution of decisions and of the reasons guiding the physician's decision on the modality to manage the secondary prevention of VTE in patients treated for a first-ever episode of VTE, after the initial 3-12 months of anticoagulation therapy.

The secondary objective is the collection of data during the follow-up: the frequency of thromboembolic complications, of bleeding complications, or death from any cause.

03

Conditions studied

  • Venous Thromboembolism

Keywords

  • Deep vein thrombosis Anticoagulant Treatment
  • Lower limbs
  • Pulmonary embolism
  • Oral Anticoagulant Treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients of any ethnicity having had a first-ever event of provoked or unprovoked DVT of the lower limbs and/or PE given maintenance anticoagulants (NOACs, VKAs, or LMWHs) according to the local procedures (usually for 3 to 12 months) and to be re-evaluated to decide the treatment to be prescribed after such period by the attending physicians

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. subjects who provided a written and authorization for disclosure of protected health information;
  2. male and female adult or elderly patients of any ethnicity having had a first-ever event of provoked or unprovoked DVT of the lower limbs and/or PE and treated with oral anticoagulant
  3. for whom the center is in possession of all the data relevant to the index event;
  4. having a permanent reference contact.

Exclusion criteria

Exclusion Criteria:

  1. subjects \<18 years old;
  2. subjects unable or unwilling to issue the written ;
  3. subjects for whom the information relevant to the index event are incomplete or inaccessible to the Investigator;
  4. subject in whom the index event was a DVT not of the lower limbs;
  5. subjects with of less than 2 years;
  6. subjects participating in any other clinical study, regardless of its nature;
  7. subjects considered, by the attending physician, unable to comply with the study procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (actual)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Number of patients who continue or stop the anticoagulant treatment

    Registration of number of patients who continue or stop the treatment; registration of type reasons guiding the attending physician's decision on the management of secondary prevention (eg: Bleeding score, laboratory test, presence of residual vein trombosis, risk or recurrence)

    Time frame: From the end of the 3rd month to the end of 12th month of anticoagulant treatment

Secondary outcomes

  1. Frequence of adverse events during follow-up

    the frequency of thromboembolic complications, of bleeding complications, or death from any cause monitored during the follow-up.

    Time frame: Frome the first day of enrollment up to 24 monhts

07

Study locations

1 site
  • Clinical Trial Centre, MATMED
    Hodonín, 695 01, Czechia
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Dec 2021, 46 months.

Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's 46 months is close to that.

Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2020
First posted
Nov 30, 2020
StartActual
Feb 1, 2018
Primary completionActual
Dec 30, 2021
CompletionActual
Feb 28, 2022
Last update
Mar 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04646993
Lead sponsor
Arianna Anticoagulazione Foundation
Responsible party
Sponsor
First posted
Nov 30, 2020
Start date
Feb 1, 2018
Primary completion
Dec 30, 2021
Completion
Feb 28, 2022
Last update
Mar 11, 2022

Study contacts

Jiří Matuška, Prof
study director · Clinical Trial Centre, Hodonin, Czech Republic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion